HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Homeopathic Market Doesn't 'Disappear' – FDA Forced To Act

Executive Summary

"This was an area that the agency thought was just going to disappear on its own," says Freddie Ann Hoffman, who chaired FDA homeopathic working group that helped develop CPG adopted in 1988 to allow sales of homeopathics to continue without pre-market approval.

You may also be interested in...



Homeopathic Firm Rebrands As Hyland’s Naturals With Shift To Focus On Supplement Market

Hyland’s Naturals focused for nearly 120 years on providing consumer health products in the pediatric and general wellness categories and is expanding into the women’s health and pet categories. Also will launch more than 20 natural wellness products over the next year.

More US COVID-19 Warnings: India Homeopathy Clinic, California Colloidal Silver Seller

Dr. Dhole’s Sushanti gets US FDA warning for claiming homeopathy could keep COVID-19 "under control" while Honey Colony is latest colloidal silver supplement marketer warned about claiming the products could prevent the disease.

US Health Market In 2019: Unfinished Business Leaves Lasting Impression

Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.

Related Content

Topics

UsernamePublicRestriction

Register

RS149359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel